Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/224689
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of- opportunity SOLTI TOT-HER3 pre-operative study
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Background: Patritumab deruxtecan (HER3-DXd) is a human epidermal growth factor receptor 3 (HER3)-directed antibody-drug conjugate composed of a fully human anti-HER3 monoclonal antibody (patritumab) covalently linked to a topoisomerase I inhibitor payload via a stable, tumor-selective, tetrapeptide-based cleavable linker. TOT-HER3 is a window-of-opportunity study designed to assess the biological activity, measured by CelTIL score [= -0.8 × tumor cellularity (in %) + 1.3 × tumor-infiltrating lymphocytes (TILs) (in %)], and clinical activity of HER3-DXd during short-term (21 days) pre-operative treatment in patients with primary operable HER2-negative early breast cancer. Patients and methods: Patients with previously untreated hormone receptor-positive/HER2-negative tumors were allocated to one of four cohorts according to baseline ERBB3 messenger RNA expression. All patients received one dose of HER3-DXd 6.4 mg/kg. The primary objective was to evaluate change from baseline in CelTIL score. Results: Seventy-seven patients were evaluated for efficacy. A significant change in CelTIL score was observed, with a median increase from baseline of 3.5 (interquartile range, -3.8 to 12.7; P = 0.003). Among patients assessable for clinical response (n = 62), an overall response rate of 45% was observed (tumor measurement by caliper), with a trend toward an increase in CelTIL score among responders compared with non-responders (mean difference, +11.9 versus +1.9). Change in CelTIL score was independent of baseline ERBB3 messenger RNA and HER3 protein levels. Genomic changes occurred, including switching toward a less proliferative tumor phenotype based on PAM50 subtypes, suppression of cell proliferation genes, and induction of genes associated with immunity. Treatment-emergent adverse events were observed in 96% of patients (14% grade ≥3); most common were nausea, fatigue, alopecia, diarrhea, vomiting, abdominal pain, and neutrophil count decrease. Conclusions: A single dose of HER3-DXd was associated with clinical response, increased immune infiltration, suppression of proliferation in hormone receptor-positive/HER2-negative early breast cancer, and a tolerable safety profile consistent with previously reported results. These findings support further study of HER3-DXd in early breast cancer.
Matèries
Matèries (anglès)
Citació
Citació
SANTHANAGOPAL, Anu, SELLAMI, Dalila, VILLACAMPA, Guillermo, FERRERO CAFIERO, Juan manuel, PASCUAL, Tomás, PRAT APARICIO, Aleix, VIDAL ESPINAR, Miquel, MARTÍNEZ SÁEZ, Olga, PARÉ BRUNET, Laia, GONZÁLEZ FARRÉ, Blanca, SANFELIU, Esther, CIRUELOS, Eva, ESPINOSA BRAVO, Martin, PERNAS, Sònia, IZARZUGAZA, Y., ESKER, Stephen, OLIVEIRA, Mafalda, FALATO, Claudette, CEJALVO ANDÚJAR, Juan miguel, MARGELÍ VILA, Mireia, TOLOSA, Pablo, SALVADOR BOFILL, Francisco javier, CRUZ JURADO, Josefina, ARUMI DE DIOS, Miriam, LUNA BARRERA, Ana maría, GUERRA, Juan antonio, FAN, Pang-dian, PARUL, Patel. Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of- opportunity SOLTI TOT-HER3 pre-operative study. _Annals of Oncology_. 2023. Vol. 34, núm. 8, pàgs. 670-680. [consulta: 21 de gener de 2026]. ISSN: 0923-7534. [Disponible a: https://hdl.handle.net/2445/224689]